Early PCSK9 inhibitor for stroke recovery
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether giving a PCSK9 inhibitor (a type of cholesterol-lowering medicine) early after a stroke can improve recovery and lower 'bad' cholesterol. It is for people who have had a non-cardioembolic stroke (not from a heart problem) caused by hardening of the arteries.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a stroke caused by hardening of the arteries (atherosclerosis), not from a heart problem.
- Your stroke started within the last 7 days.
- You are 19 years old or older.
- You have a significant narrowing (stenosis) in one of the major arteries in your brain or neck.
- Your stroke symptoms are mild to moderate (NIHSS score 15 or less at admission).
- You can take statins and the study drug (PCSK9 inhibitor).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether quickly starting an aggressive cholesterol-lowering treatment after a stroke improves recovery. It is for people who are about to have a procedure to remove a large blood clot from their brain.
This trial tests whether a cholesterol-lowering medication called evolocumab (a PCSK9 inhibitor) can help people recover better after a specific type of stroke caused by clogged arteries. The study checks if lowering cholesterol further than usual statins do improves stroke outcomes and is safe.
This trial tests whether a PCSK9 inhibitor (a drug that lowers cholesterol) can help people who recently had a stroke caused by narrowing of an artery inside the skull. It aims to see if the drug can prevent more strokes and improve recovery.
This trial tests if adding a PCSK9 inhibitor (a newer cholesterol-lowering medicine) to standard care helps people who had a stroke from a large artery blockage and had a clot-removal procedure. It may lower bad cholesterol further and reduce the risk of another stroke.
This trial studies whether starting a PCSK9-blocking medicine early after a specific type of heart attack can improve heart outcomes. You may be eligible if you have a STEMI heart attack soon, are planning a procedure to open the blocked artery, and meet safety and pregnancy criteria.
This trial tests whether a cholesterol-lowering medication (PCSK9 inhibitor) can help prevent further strokes in people who have recently had a stroke or mini-stroke due to a narrowed artery in the brain. It is for adults 30 to 80 years old who meet specific health criteria.
Hear when a new PCSK9 Inhibitor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.